ENANTA PHARMACEUTICALS, INC Impairment of Long-Lived Assets Held-for-use
ENANTA PHARMACEUTICALS, INC (ENTA) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2025-11-19
- ENANTA PHARMACEUTICALS, INC impairment of long-lived assets held-for-use for fiscal 2025 was $0.00.
- ENANTA PHARMACEUTICALS, INC impairment of long-lived assets held-for-use for fiscal 2024 was $0.00.
- ENANTA PHARMACEUTICALS, INC impairment of long-lived assets held-for-use for fiscal 2023 was $0.00.
- ENANTA PHARMACEUTICALS, INC impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|
| 2025-09-30 | $0.00 10-K · filed 2025-11-19 |
| 2024-09-30 | $0.00 10-K · filed 2024-11-27 |
| 2023-09-30 | $0.00 10-K · filed 2023-11-22 |
| 2022-09-30 | $0.00 10-K · filed 2022-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |